dc.contributor.author |
Osman, Rasha Ibrahim |
|
dc.contributor.author |
Supervisor, - Samia Mahdi Ahmed |
|
dc.date.accessioned |
2013-09-18T11:58:46Z |
|
dc.date.available |
2013-09-18T11:58:46Z |
|
dc.date.issued |
2012-08-01 |
|
dc.identifier.citation |
Osman,Rasha Ibrahim.Assessment of Serum CA 125 Response to Chemotherapy in Sudanese Female with Ovarian Cancer Referred to Radiation and Isotope Centre in Khartoum State/Rasha Ibrahim Osman;Samia Mahdi Ahmed.-Khartoum:Sudan University of Science and Technology,Medical Laboratory Science,2012.-56p.:ill.;28cm.-M.Sc. |
en_US |
dc.identifier.uri |
http://repository.sustech.edu/handle/123456789/1622 |
|
dc.description |
Thesis |
en_US |
dc.description.abstract |
Purpose this study was conducted to assess the response of CA125
levels to carboplatin-paclitaxel chemotherapy in Sudanese females with
ovarian carcinoma
Patients and Methods in a cross sec onal study, 40 female pa ents with
histologically proven ovarian carcinoma who were referred to Radiation
and Isotope Centre, Khartoum/Sudan, were enrolled. They all were
receiving carboplatin-paclitaxel chemotherapy. Radioimmunoassay was
used to measure serum CA125 within first day of referral as an initial
sample, then after the first month of chemotherapy and after the
second month of chemotherapy. The pa ents age range was 24-70
years, the chemotherapy dura on ranged from 2-12 months.
Results The mean serum CA125 levels were 75.09, 34.6, and 36.9 U/ml
at the initial samples, first month samples and second month samples of
chemotherapy, respectively. In comparison with the ini al CA125 level,
both level after the first month of chemotherapy and level after the
second month of chemotherapy showed a significant decline
(P=0.032,0.030) respec vely. While CA125 level from the first to the
second month of chemotherapy showed insignificant decline (P=0.85).
There was no correla on between the response of CA125 and the
duration of chemotherapy (correla on coefficient=0.3)
Conclusion Serial changes in CA125 can be used as a reliable indicator of
disease response or progression so that patients can be classified as
responding or progressing according to either standard or CA125
criteria. |
en_US |
dc.description.sponsorship |
Sudan University of Science and Technology |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Sudan University of Science and Technology |
en_US |
dc.subject |
Serum-Assessment |
en_US |
dc.subject |
Ovarian Cancer |
en_US |
dc.subject |
Chemotherapy |
|
dc.title |
Assessment of Serum CA 125 Response to Chemotherapy in Sudanese Female with Ovarian Cancer Referred to Radiation and Isotope Centre in Khartoum State |
en_US |
dc.title.alternative |
تقویم إستجابة مستوى مستضد الأنتیجین سي أي 125 للعلاج الكیماوي في الإناث السودانیات المصابات بسرطان المبیض المحالات لمركز العلاج بالأشعة والطب النووي بولایة الخرطوم |
en_US |
dc.type |
Thesis |
en_US |